Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p166 | Cell biology: osteoblasts and bone formation | ECTS2016

Primary osteoblast culture from domestic dog (Canis lupus familiaris)

Perpetuo Ines Pedro , Meeson Richard , Pitsillides Andrew , Doube Michael , Orriss Isabel

Effects of whole bone scaling on isolated osteoblast behaviour are unknown. With two orders of magnitude range in body mass, dog breeds are well-suited to determine such relationships.Femoral heads from three canine hip replacement surgeries were collected. Bone fragments were washed in PBS+AB/AM, trypsin-digested and incubated in 0.2% collagenase. Cells from resultant supernatant were seeded in DMEM+10% FCS+AB/AM at 37 °C, 5% CO2, g...

ba0006oc7 | (1) | ICCBH2017

The effect of antenatal iron supplementation on fibroblast growth factor-23 concentration in mothers and infants: a randomised controlled trial in rural Kenya

Braithwaite Vickie , Demir Ayse , Mwangi Martin , Andang'O Pauline , Prentice Andrew , Prentice Ann , Verhoef Hans

Objectives: Murine studies have shown that iron deficiency during pregnancy can cause abnormal phosphate and bone metabolism in offspring by elevating concentrations of fibroblast growth factor-23 (FGF23). FGF23 exists in plasma as an intact phosphate- and vitamin D-regulating hormone and its C-terminal fragment, a cleavage product that possibly antagonises the intact hormone. These findings are pertinent to low-income countries, where the prevalence of iron deficiency in preg...

ba0006oc23 | (1) | ICCBH2017

Sustained radiographic and functional improvements with asfotase alfa treatment from up to 7 years in children with hypophosphatasia

Whyte Michael P. , Rockman-Greenberg Cheryl , Moseley Scott , Denker Andrew E. , McAlister William H.

Objective: Children with hypophosphatasia (HPP) treated with asfotase alfa in a Phase 2 study (NCT00952484) and its open-label extension (NCT01203826) experienced significant improvements in skeletal mineralization and physical function that were sustained through 5 years of treatment (1). Herein, we report data from these studies with a maximum of 7 years of treatment.Methods: Children with HPP aged 6–12 years at baseline received asfotase alfa (3 ...

ba0006oc25 | (1) | ICCBH2017

Biochemical and physical function outcomes after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia: phase 2 study results

Kishnani Priya S. , Rockman-Greenberg Cheryl , Denker Andrew E. , Moseley Scott , Whyte Michael P.

Objective: To evaluate safety and efficacy after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia (HPP) in a Phase 2, open-label, randomized, dose-ranging study (NCT01163149).Methods: Treatment with subcutaneous asfotase alfa 0.3 or 0.5 mg/kg per d was compared with no treatment (control) for 6 months in patients aged 13–66 years. After 6 months, all patients (treatment and control groups) received active treat...

ba0006p086 | (1) | ICCBH2017

Feasibility and reproducibility using HRpQCTII in children and adolescents

Kent Kyla , Whalen Jessica , Strickland Ariana , Leonard Mary , Burghardt Andrew J.

We recruited 60 healthy volunteers ages 5 to 21 to perform scan-rescan precision tests on the XtremeCT II. Participants were positioned in a carbon fiber immobilization cast. iPad-based video content was used to facilitate motion-free compliance. Distal radius and tibia scans were acquired starting 2 mm proximal to the proximal margin of the growth plate or growth plate remnant. Diaphyseal radius and tibia scans were centered at an offset from the same landmark, corresponding ...

ba0006p099 | (1) | ICCBH2017

Bone strength and microarchitectural deficits in children with cystinosis

Burghardt Andrew , Kent Kyla , Long Jin , Whalen Jessica , Phelps Maira , Leonard Mary

Children with cystinosis have numerous risk factors for impaired bone accrual. We used state-of-the-art quantitative imaging of bone microarchitecture (HR-pQCT) to measure trabecular and cortical microstructure and bone strength in children and adolescents (5-20yrs) with cystinosis. We enrolled 20 cystinosis patients and recruited 34 healthy age- and gender- matched controls. Distal radius and tibia HR-pQCT scans (XtremeCT II, Scanco Medical) were acquired 2...

ba0007oc10 | (1) | ICCBH2019

Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

Baik Andrew , Aaron Nina , Birnbaum Matthew , Calafati Philip , Schoenherr Christopher , Economides Aris , Cygnar Katherine

Objectives: Lysosomal diseases (LDs) are a heterogenous group of 40+ genetic disorders that can affect virtually all organs and systems, including the skeletal system. They are often caused by the loss of an enzyme critical for the breakdown of macromolecules in the lysosome, leading to accumulation of these substrates and subsequent lysosomal dysfunction. Enzyme replacement therapy (ERT) is the primary treatment option for many LDs, but several issues hinder the efficacy of t...

ba0007p90 | (1) | ICCBH2019

Osteogenesis imperfecta due to FKBP10 mutation- shift from high to low bone turnover

Lenherr-Taube Nina , Harrington Jennifer , Murphy Anne , Filipowski Kornelia , Kin On Wong Andy , Horward Andrew , Sochett Etienne

Background: Osteogenesis imperfecta (OI) due to FKBP10 mutation is a rare variant of OI. FKBP10 encodes for FKBP65, a molecular chaperon that interacts with type I procollagen to prevent premature fibril formation and plays a role in collagen crosslinking. Defects in FKBP65 result in a spectrum of moderate to severe OI with remarkable variability in phenotypes.Presenting problem: The patient is the first child of non-consanguineous Caucasian parents. She...

ba0007p212 | (1) | ICCBH2019

Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model

Nannuru Kalyan , Jimenez Johanna , Brydges Susannah , Murphy Andrew , Economides Aris , Hatsell Sarah

Hereditary multiple osteochondromas (HMO) is an autosomal dominant rare genetic disorder due to LOF heterozygous mutations in EXT1 or EXT2 genes. HMO is an unmet medical condition where patients often requiring multiple surgeries. HMO is characterized by painful cartilaginous capped bony outgrowths at the growth plate (GP) regions of long bones, ribs and other skeletal elements. The molecular mechanism by which these mutations lead to disease is unknown. Mutations in EXT1 and ...

ba0002is18biog | (1) | ICCBH2013

Obesity and skeletal health

Dimitri Paul

Biographical DetailsDr P Dimitri studied Medicine at the University of St Andrew’s in Scotland and the University of Manchester where he received a medal in pathology and a distinction in Paediatrics. In 2010 he was awarded a PhD in Medicine and the Michael Blacow Award from the Royal College of Paediatrics and Child Health for his work on the relationship of fat and bone in children...